| Aug 13 |
PAVmed Inc. (PAVM) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
PAVmed Non-GAAP EPS of -$0.84, revenue of $979M
|
| Aug 13 |
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
|
| Aug 13 |
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
|
| Aug 12 |
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
|
| Aug 11 |
PAVmed Q2 2024 Earnings Preview
|
| Aug 8 |
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
|
| Aug 6 |
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
|
| Aug 5 |
Lucid Diagnostics to Participate in Upcoming Investor Conferences
|
| Jul 30 |
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
|
